Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HX Diagnostics has expanded its license and development agreement with Nanogen to include the development of additional rapid, point-of-care diagnostics for respiratory infectious diseases.
Subscribe to our email newsletter
As part of the three-year agreement, the companies will employ the same underlying technology used in their previously announced joint project, a diagnostic for the differential diagnosis of seasonal and pandemic influenza.
The companies are currently in the final stages of development on a highly sensitive diagnostic assay that can simultaneously detect multiple strains and subtypes of influenza, including avian influenza, with one simple and rapid test.
The fluID rapid influenza test is said to be a low cost device utilizing high affinity monoclonal antibodies and proprietary lateral flow technology from Nanogen.
The same proprietary lateral flow technology and device design will be used in the newly announced development programs. Once development is complete, HX Diagnostics will be granted exclusive commercial license to manufacture and market the resulting products upon regulatory approval.
Wendy Benson, president and CEO of HX Diagnostics, said: “The expanded agreement with Nanogen gives us the opportunity to open up our potential market by providing full panels of diagnostics for respiratory illnesses.”